VIR BIOTECHNOLOGY INC (VIR) Stock News

USA - NASDAQ:VIR - US92764N1028 - Common Stock

5.7 USD

+0.14 (+2.52%)

Last: 11/21/2025, 12:42:46 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VIR Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

12 days ago - By: Stocktwits - Mentions: GILD

News Image

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown

12 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

16 days ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

4 months ago - By: The Motley Fool

Vir (VIR) Q2 Revenue Drops 61%

4 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

14 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

16 days ago - By: Zacks Investment Research - Mentions: VTGN

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

16 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

18 days ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

23 days ago - By: Zacks Investment Research - Mentions: GSK JNJ

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

a month ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

a month ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

2 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

3 months ago - By: Yahoo Finance - Mentions: LLY HSBC SBAC T-PA ...

Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls

3 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

4 months ago - By: Zacks Investment Research - Mentions: FEMY

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

4 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

6 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

6 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

6 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

7 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

7 months ago - By: Zacks Investment Research - Mentions: AGEN

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results